A R/S is very possible; but I like that Nasdaq has lowered the listing requirements to $2 (instead of $4). In translation; it would be a less painful split basis. We have now have taken a major step for the uplisting; it wont be long before this reality happens.
My dream prediction: the company nails the BD partnership and one other MANF Orphan indication partnership (perhaps Retinosis Pigmentosis, Diabetes, etc.) ......and we catapult to closer to the $1 range. A 4 for 1 R/S (or less) would work for me (to get above $2).
News 
Market Data 
Discover 
